GPT and metabolic dysfunction-associated steatotic liver disease: A 5% or greater weight reduction for one year was associated with ALT improvement and a 3.6-fold increased rate of ALT normalization, suggesting that a 5% reduction in body weight could be recommended as an initial therapeutic target for NAFLD patients4.